title: Aging with HIV: a practical review.
abstract: The worldwide elderly population is expected to grow by an additional 694 million people by 2025. By that time, there will be approximately two billion elderly people in the world, most of whom (80%) will be living in developing countries. Based on recent estimates, this population will number over 40 million in 2030 in Brazil and a consequent increase in governmental spending for this population can be expected. Since highly active antiretroviral therapy became available in the mid-1990s, the life expectancy of people living with HIV has increased significantly. Approximately 12 million life years were added to the world between 1996 and 2008 as a consequence of wider access to highly active antiretroviral therapy. In Brazil, the incidence of AIDS among the population aged ≥50 years doubled between 1996 and 2006. The development of antiretroviral therapy has allowed individuals diagnosed at a younger age to live longer, which partially explains the aging tendency associated with the HIV/AIDS epidemic. It is estimated that by 2015, subjects aged ≥50 years will represent 50% of the people living with HIV undergoing clinical treatment. This scenario presents some challenges, including the fact that the diagnosis of HIV tends to be delayed in older patients compared to younger patients because the symptoms of HIV can be confused with those of other common diseases among the elderly and also because healthcare professionals do not consider this population to be at high risk for HIV infection. In regard to the individuals diagnosed with HIV, a further challenge is presented by the morbidity normally associated with aging. Finally, the elderly also exhibit higher susceptibility to the toxic effects and pharmacological interactions of medications. The present article reviews the literature regarding the profile of HIV infection among individuals aged ≥50 years focusing on practical features related to the clinical approach and long-term follow-up of this population.
authors.affiliation: Fundação Oswaldo Cruz, Instituto de Pesquisa Clínica Evandro Chagas, HIV/AIDS Clinical Research Center, Rio de Janeiro, RJ, Brazil.
authors.forename: Sandra Wagner
authors.initials: SW
authors.lastname: Cardoso
authors.forename: Thiago Silva
authors.initials: TS
authors.lastname: Torres
authors.forename: Marilia
authors.initials: M
authors.lastname: Santini-Oliveira
authors.forename: Luana Monteiro Spindola
authors.initials: LM
authors.lastname: Marins
authors.forename: Valdiléa Gonçalves
authors.initials: VG
authors.lastname: Veloso
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000375:Aging; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001938:Brazil / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D020276:HIV Long-Term Survivors / Q000706:statistics & numerical data; D006801:Humans; D008017:Life Expectancy / Q000639:trends; D008875:Middle Aged; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents
keywords: AIDS; Aging; Brazil; Comorbidity; Elderly; HAART; HIV